Minimize Uncertainty – Make Informed Decisions – Succeed

Lucid Diligence Brief - Tech

Lucid Diligence Brief: ZipBio licenses its AI-designed GA AAV program to MeiraGTx

February 4, 2026clinical trials,market access,AAV,artificial intelligence,gene therapy,Regulatory,ophthalmology,biopharma,Lucid Diligence Brief,payer accessdiligence

Lucid Diligence Brief: ZipBio licenses its AI-designed GA AAV program to…

by Timos Papagatsias

EAHAD 2026_Preview_by_LucidQuest

EAHAD 2026 PREVIEW: Key Highlights to Watch

February 3, 2026factor replacement therapy,von Willebrand disease,Our Insights,pediatric hemophilia,hemophilia,prophylaxis optimization,Hemophilia A,real-world evidence,hemophilia b,Generative AI,Emicizumab,concizumab,Conference Previews,AI in hematology,Marstacimab,EAHAD 2026rare bleeding disorders,non-factor therapies

EAHAD 2026 at a Glance Get ready for EAHAD 2026. LucidQuest’s preview…

by LucidQuest

Endocrinology

Endocrinology Today—February 3, 2026

February 3, 2026BioPharma and Tech News,Novo Nordiskosteoporosis,type 2 diabetes,Endocrinology News,Sciwind Biosciences,Diabetic kidney disease,Diabetic peripheral neuropathic pain,Pilavapadin,Closed-loop insulin delivery

This Endocrinology weekly update covers regulatory actions, clinical progress,…

by LucidQuest

Obesity Weekly News

Obesity Video Recap—February 3, 2026

February 3, 2026dual GLP-1/GIP agonist,Hanmi,astrazeneca,JW Pharmaceutical,msd,Olatorapetide,roche,Praluent,BioPharma and Tech News,Efinopegdutide,Regeneron,Elecoglipron,Ascletis,Muscle Atrophy Inhibitors,oral GLP-1,GLP-1 Adjuncts,Obesity News,Chugai Pharmaceutical,Efpeglenatide,triple agonist,YuhanCSPC,Corxel

This biweekly Obesity video recap highlights key developments across clinical…

by LucidQuest

Obesity Weekly News

Obesity Today—February 3, 2026

February 3, 2026astrazeneca,roche,BioPharma and Tech News,Novo Nordisk,Eli Lilly,type 2 diabetes,GLP-1 receptor agonist,oral GLP-1,Obesity NewsMetabolic syndrome,dual GLP-1/GIP agonist

This weekly update in Obesity and Metabolic Disease highlights major regulatory…

by LucidQuest

Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Galderma resubmits RelabotulinumtoxinA to the FDA

February 3, 2026clinical trials,FDA,Regulatory,biopharma,CMC,Lucid Diligence Brief,MHRA,diligence,competitive landscape,aesthetics,neuromodulatorscash pay

Lucid Diligence Brief: Galderma resubmits RelabotulinumtoxinA to the FDA…

by Timos Papagatsias

Oncology News

Oncology Video Recap—February 2, 2026

February 2, 2026BioPharma and Tech News,Ovarian Cancergastric cancer,Eli Lilly,antibody drug conjugate,Oncology News,muscle-invasive bladder cancer,Cholangiocarcinoma,Gastrointestinal stromal tumor,HR+/HER2- breast cancer,FDA Priority Review

This biweekly video recap in oncology summarizes regulatory actions, late-stage…

by LucidQuest

Artificial_Intelligence

AI in Healthcare and Digital Health Today—February 2, 2026

February 2, 2026Heart Failure Society of America,LLMs,digital endpoints,DeepSeek-V3-FW,Insilico Medicine,Gemini 2.0 Flash,BioPharma and Tech News,ChatGPT-4.5,Microsoft,Explainable AI (XAI),mammography AI,QLattice,Bristol Myers Squibb,Compute-in-memory,AI in Healthcare and Digital Health,Edge AI,agentic AI,Knowledge graphs,Sword Health,Retrieval-augmented generation (RAG),organizations OpenAI,CKD Prediction,Kaia Health,Speech Biomarkers,Janux Therapeutics,Exergame RehabilitationSamsung,Digital Medicine Society

This week's AI in Healthcare and Digital Health update highlights AI’s…

by Timos Papagatsias

Onco_background

Oncology Today—February 2, 2026

February 2, 2026immunotherapy,precision oncology,BioPharma and Tech News,melanoma,Oncology News,muscle-invasive bladder cancer,Triple-negative breast cancer,Cholangiocarcinoma,FDA Breakthrough Therapy DesignationGastrointestinal stromal tumor,Metastatic hormone-sensitive prostate cancer

This weekly update in oncology covers regulatory actions, clinical progress,…

by LucidQuest

Hematology

Hematology Today—February 2, 2026

February 2, 2026hemophilia,BCMA,Multiple Myeloma,BioPharma and Tech News,Daratumumab,Eli Lilly,BTK Inhibitors,Johnson & Johnson,Hematology News,CAR T cell therapyAL amyloidosis,essential thrombocythemia

This weekly update in Hematology covers regulatory actions, late-stage clinical…

by LucidQuest

Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Kyowa Kirin regains rocatinlimab rights from Amgen

February 2, 2026clinical trials,market access,Regulatory,Atopic Dermatitis,dermatology,biopharma,Lucid Diligence Brief,payer access,diligence,HTAOX40 pathway

Lucid Diligence Brief: Kyowa Kirin regains rocatinlimab rights from Amgen…

by Timos Papagatsias

Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Ultragenyx UX111 BLA resubmission

February 1, 2026clinical trials,gene therapy,Regulatory,rare disease,pediatrics,biopharma,Lucid Diligence Brief,payer access,diligence,MPS IIIAAAV9

Lucid Diligence Brief: Ultragenyx UX111 BLA resubmission Professional audiences…

by Timos Papagatsias

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required
You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.